Abstract
Enalapril maleate (EM) is a widely used anti-hypertensive drug which is unstable when mixed with excipients. Enalaprilate and diketopiperazine (DPK) are the main degradation products of enalapril. The in situ preparation of enalapril sodium salt (NaE) has been used to improve drug stability in dosage forms; however, gas release and product rejection ensue when the chemical reaction for obtaining the sodium salt is not completely finished before packaging. This study evaluated the effect of stearic acid (SA) on enalapril stability in microcrystalline cellulose (MCC) pellets containing EM or NaE. MCC pellets containing SA were prepared by the extrusion–spheronization technique and characterized. Enalapril stability and dissolution were then evaluated. DPK and enalaprilate formation were reduced by the addition of SA in pellets containing EM. The overall enalapril degradation in these formulations was lower when compared with pellets containing EM or even NaE prepared without SA. The immediate-release characteristic was maintained by the addition of 5% crospovidone to all the formulations tested. The incorporation of SA into NaE pellets resulted in unexpected enalapril degradation, caused by the interaction of these compounds, as suggested by a thermal analysis of the SA–NaE binary mixture. The findings presented here showed that formulations containing SA could substitute the formation of NaE, since they provide better enalapril stability in solid dosage forms. In addition, it is suggested that the stabilization effects would be observed for other N-carboxyalkyl dipeptide analogs with angiotensin converting enzyme inhibition activity, since these new entities share the same degradation pathway of enalapril.
Similar content being viewed by others
References
Al-Omari MM, Abdelah MK, Badwan AA, Jaber AMY. Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations. J Pharm Bio Anal. 2001;25:893–02.
Lima DM, Santos LD, Lima EM. Stability and in vitro release profile of enalapril maleate from different commercially available tablets: possible therapeutic implications. J Pharm Bio Anal. 2008;47:934–7.
Resende RLO, Santoro MIRM, Matos JR. Stability and compatibility study on enalapril maleate using thermoanalytical techniques. J Ther Anal Cal. 2008;93:881–6.
Cotton ML, Wu DW, Vadas EB. Drug-excipient interaction study of enalapril maleate using thermal analysis and scanning electron microscopy. Int J Pharm. 1987;40:129–42.
Merslavic SM, Jozica Razen NM, Ales Rotar L. Stable formulation of enalapril salt, a process for the preparation thereof and the use thereof. WO Patent. 1994.
Zoppi A, Garnero C, Linck YG, Chattah AK, Monti GA, Longhi MR. Enalapril: β-CD complex: stability enhancement in solid state. Carbohydr Polym. 2011;86:716–21.
Kowalski J, Kalb O, Joshi YM, Serajuddin ATM. Application of melt granulation technology to enhance stability of a moisture sensitive immediate-release drug product. Int J Pharm. 2009;381:56–61.
Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6 rd ed. London: Pharmaceutical Press; 2009.
Dukic-Ott A, Thommes M, Remon JP, Kleinebudd P, Vervaet C. Production of pellets via extrusion- spheronization without the incorporation of microcrystalline cellulose: a critical review. Eur J Pharm Biopharm. 2009;71:38–46.
United States Pharmacopeia 31, National Formulary, United States Pharmacopeia Convention, Rockville, 2008.
International Conference of Harmonization, Q2 (R1) Validation of analytical procedures: text and methodology, 2005, ICH, Geneva, Switzerland.
Gu L, Strickley RG. A profound solvent effect on the diketopiperazine formation of the new dipeptide angiotensin-converting enzyme inhibitor, moexipril. Int J Pharm. 1990;60:99–107.
Acknowledgments
Financial support from INCT_if and CNPQ is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cunha, T.A., Serpa, R.C., de Oliveira, A.P.M. et al. Effect of Stearic Acid on Enalapril Stability and Dissolution from Multiparticulate Solid Dosage Forms. AAPS PharmSciTech 14, 1150–1157 (2013). https://doi.org/10.1208/s12249-013-0006-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-013-0006-6